Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
<!-- Name:DistributionId Value:8825434 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value: -->…
Browsing Tag
Biogens
FDA advisors vote against effectiveness of Biogen’s ALS drug for rare and aggressive form of…
A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, U.S., on Monday, June 7, 2021.Adam Glanzman | Bloomberg | Getty ImagesThe Food and Drug Administration's independent panel of advisors on Wednesday voted against…
FDA advisors reject Biogen’s ALS drug for rare and aggressive form of the disease
A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, U.S., on Monday, June 7, 2021.Adam Glanzman | Bloomberg | Getty ImagesThe Food and Drug Administration's independent panel of advisors on Wednesday declined to…
FDA staff says Biogen’s ALS drug may have a ‘clinical benefit’ on a rare form of…
U.S. Food and Drug Administration staff on Monday said Biogen's investigational ALS drug may have a "clinical benefit" on a rare and aggressive form of the disease, despite failing a broader late-stage clinical trial last year. The staff…
FDA will review Eisai’s and Biogen’s Alzheimer’s treatment Leqembi with decision…
Andrew Brookes | Image Source | Getty ImagesThe Food and Drug Administration will make a decision on whether to fully approve Eisai's and Biogen's Alzheimer's treatment Leqembi by July 6, the companies announced on Monday.Leqembi is an…
New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease…
Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY® (diroximel fumarate) consistent with previous assessmentsPatient-reported outcomes…
Biogen’s Stock Pullback Offers a Second Chance
After slipping to its lowest level since 2013, Biogen Inc. (NASDAQ:BIIB) was all but forgotten by growth investors. That changed in dramatic fashion late last month when the biotech’s pipeline got a major boost.…
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results…
Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with systemic lupus erythematosus (SLE) compared to placeboBiogen is currently enrolling…
The FDA approved a new drug to treat Alzheimer’s, but Medicare won’t always pay for it –…
Medicare finalized its decision to restrict its coverage of Aduhelm, Biogen’s new Alzheimer’s disease drug, on April 8, 2022.
The decision means only patients who have enrolled in clinical trials will receive Medicare coverage for…
New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research…
Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm high rates of persistence and adherence…